Cargando…

Pharmacogenomics of hepatitis C infections: personalizing therapy

It is a widely held view that drug response genes have not proved as useful in clinical practice as anticipated at the start of the genomic era. An exception is in the treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon α and ribavirin. In 2009, four independ...

Descripción completa

Detalles Bibliográficos
Autores principales: Booth, David R, Ahlenstiel, Golo, George, Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580439/
https://www.ncbi.nlm.nih.gov/pubmed/23268841
http://dx.doi.org/10.1186/gm400
_version_ 1782260247786684416
author Booth, David R
Ahlenstiel, Golo
George, Jacob
author_facet Booth, David R
Ahlenstiel, Golo
George, Jacob
author_sort Booth, David R
collection PubMed
description It is a widely held view that drug response genes have not proved as useful in clinical practice as anticipated at the start of the genomic era. An exception is in the treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon α and ribavirin. In 2009, four independent genome-wide analyses identified IL28B polymorphisms that predict drug response in chronic hepatitis C (CHC). This discovery had immediate clinical impact. First, the IL28B genotype could be used to personalize therapy. In the 2 years since discovery, most of the more than 100,000 CHC patients commencing therapy for CHC in the West will have considered IL28B genotype testing. Second, the discovery has supported clinical trials for the use of the protein encoded by the gene known as interferon lambda. Third, it is expected that new insights into HCV pathogenesis will follow from studies of how IL28B affects HCV viral clearance and, ultimately, this will lead to new therapeutic strategies for CHC. This review discusses how IL28B genotyping is now used in personalizing therapy and, with the dramatically changing clinical landscape in CHC, with the advent of direct-acting antivirals, the prospects ahead.
format Online
Article
Text
id pubmed-3580439
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35804392013-12-26 Pharmacogenomics of hepatitis C infections: personalizing therapy Booth, David R Ahlenstiel, Golo George, Jacob Genome Med Review It is a widely held view that drug response genes have not proved as useful in clinical practice as anticipated at the start of the genomic era. An exception is in the treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon α and ribavirin. In 2009, four independent genome-wide analyses identified IL28B polymorphisms that predict drug response in chronic hepatitis C (CHC). This discovery had immediate clinical impact. First, the IL28B genotype could be used to personalize therapy. In the 2 years since discovery, most of the more than 100,000 CHC patients commencing therapy for CHC in the West will have considered IL28B genotype testing. Second, the discovery has supported clinical trials for the use of the protein encoded by the gene known as interferon lambda. Third, it is expected that new insights into HCV pathogenesis will follow from studies of how IL28B affects HCV viral clearance and, ultimately, this will lead to new therapeutic strategies for CHC. This review discusses how IL28B genotyping is now used in personalizing therapy and, with the dramatically changing clinical landscape in CHC, with the advent of direct-acting antivirals, the prospects ahead. BioMed Central 2012-12-26 /pmc/articles/PMC3580439/ /pubmed/23268841 http://dx.doi.org/10.1186/gm400 Text en Copyright ©2012 BioMed Central Ltd
spellingShingle Review
Booth, David R
Ahlenstiel, Golo
George, Jacob
Pharmacogenomics of hepatitis C infections: personalizing therapy
title Pharmacogenomics of hepatitis C infections: personalizing therapy
title_full Pharmacogenomics of hepatitis C infections: personalizing therapy
title_fullStr Pharmacogenomics of hepatitis C infections: personalizing therapy
title_full_unstemmed Pharmacogenomics of hepatitis C infections: personalizing therapy
title_short Pharmacogenomics of hepatitis C infections: personalizing therapy
title_sort pharmacogenomics of hepatitis c infections: personalizing therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580439/
https://www.ncbi.nlm.nih.gov/pubmed/23268841
http://dx.doi.org/10.1186/gm400
work_keys_str_mv AT boothdavidr pharmacogenomicsofhepatitiscinfectionspersonalizingtherapy
AT ahlenstielgolo pharmacogenomicsofhepatitiscinfectionspersonalizingtherapy
AT georgejacob pharmacogenomicsofhepatitiscinfectionspersonalizingtherapy